Answers are grounded in this paper and cite their sources.
Background No antiviral therapy is approved for dengue virus (DENV). Galectin-3 (Gal3), a β-galactoside-binding lectin, modulates several viral infections, but its role in DENV pathogenesis is unknown. Material and Methods Using a GFP-tagged DENV-2 reporter virus, we evaluated the effects of recombinant Gal3, Gal3 knockdown and Gal3 overexpression. Viral attachment, internalization, NF-κB signaling and cytokine expression were analyzed, together with molecular docking of Gal3 to the DENV envelope (E) protein. Disease outcomes were assessed in intracerebrally inoculated neonatal Gal3-knockout (Gal3-KO) mice. Results DENV-2 infection down-regulated endogenous Gal3. Extracellularly, recombinant Gal3 reduced DENV-2 infectivity and progeny production in a dose-dependent manner, and conditioned medium containing cell-secreted Gal3 had a similar effect. The inhibition was reversed by lactose, and by the Gal3-neutralizing antibody B2C10, but not by sucrose or control IgG. Gal3 bound the E protein and reduced viral attachment and internalization. In silico docking was compatible with Gal3 engagement at both E glycosylation sites, with aggregate scores favoring Asn67. Knockdown of endogenous Gal3 enhanced, and overexpression suppressed, DENV-2 replication. Gal3 also amplified NF-κB activation and the expression of IL-6, IL-8, TNF-α and IL-1β, without altering type I interferon transcripts. In vivo , infected Gal3-KO neonates showed earlier mortality, higher brain viral loads and more severe neuropathology than wild-type mice. Conclusions Gal3 restricts DENV-2 by binding the viral envelope glycoprotein and reducing viral entry, and by enhancing NF-κB-dependent pro-inflammatory responses. Gal3 deficiency worsens disease in vivo , and Gal3 is a candidate host-directed target against dengue.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: